

Outlook Therapeutics, Inc. Logo

Outlook Therapeutics® to Present at the Virtual Investor 2023 Companies to Watch Event

January 9, 2023

Live video webcast presentation on Tuesday, January 17th at 11:00 AM ET

ISELIN, N.J., Jan. 09, 2023 (GLOBE NEWSWIRE) -- [Outlook Therapeutics, Inc.](#) (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that [Russ Trenary, President and Chief Executive Officer](#) of Outlook Therapeutics will present at the [Virtual Investor 2023 Companies to Watch Event](#) on Tuesday, January 17, 2023 at 11:00 AM ET.

A [live video webcast](#) of the presentation will be available on the [Events](#) page of the [Investors](#) section of Outlook Therapeutics' website ([outlooktherapeutics.com](#)). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.

About Outlook Therapeutics, Inc.

Outlook Therapeutics is a biopharmaceutical company working to develop and launch ONS-5010/ LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD, DME and BRVO. The FDA accepted Outlook Therapeutics' BLA submission for ONS-5010 to treat wet AMD with a PDUFA goal date of August 29, 2023. The submission is supported by Outlook Therapeutics' wet AMD clinical program, which consists of three clinical trials: NORSE ONE, NORSE TWO, and NORSE THREE. If ONS-5010 ophthalmic bevacizumab is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan, and other markets. As part of the Company's multi-year commercial planning process, and in anticipation of potential FDA approval in August 2023, Outlook Therapeutics and AmerisourceBergen have entered into a strategic commercialization agreement to expand the Company's reach for connecting to retina specialists and their patients. AmerisourceBergen will provide third-party logistics (3PL) services and distribution, as well as pharmacovigilance services in the United States. For more information, please visit [www.outlooktherapeutics.com](#).

CONTACTS:

Media Inquiries:

Anna Army
Account Supervisor
LaVoie Health Science
T: 617-351-0246
aarmy@lavoiehealthscience.com

Investor Inquiries:

Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 833.475.8247
OTLK@jtcir.com



Source: Outlook Therapeutics, Inc.